Zurex Pharma Inc., a Middleton, Wisc.-based life sciences company, has raised $6.2m in Series A financing.
The round was led by Baird Venture Partners and the State of Wisconsin Investment Board led the round, with participation from Wisconsin Investment Partners, Peak Ridge Capital and undisclosed individuals.
The company intends to use the funding to develop its products.
Led by President and CEO Carmine Durham, Zurex develops and commercializes a portfolio of innovative antimicrobial products designed to prevent healthcare acquired infections with a focus on surgical site wounds and catheter-related infections.
In conjunction with the funding, Michael Liang, Ph.D., Partner at Baird Venture Partners and Fred Robertson, M.D., Baird Venture Partners Operating Partner, will join the company’s Board of Directors.